Subjects to be considered in partial replicate BE study [RSABE / ABEL]

posted by d_labes  – Berlin, Germany, 2015-01-08 10:03 (3827 d 15:44 ago) – Posting: # 14246
Views: 30,249

Dear Cher,

❝ One more query,why a subject with two periods, each with reference, will not be included in the pharmacokinetic analysis for SWR?


I didn't not recommend this. I only pointed you to the problem in your cited rules.

I myself would include all subjects with at least 2 periods, regardless which formulation was applied, into PK and statistical analysis.

The rest is done automatically: Subjects with Reference only will not contribute to the BE decision but to the sWR estimation, subjects with Test and only one Reference will contribute to the BE decision but not to the sWR estimation.

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
23,425 posts in 4,928 threads, 1,676 registered users;
42 visitors (0 registered, 42 guests [including 6 identified bots]).
Forum time: 02:48 CEST (Europe/Vienna)

No problem can stand the assault of sustained thinking.    Voltaire

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5